A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Pain Clinical Trial

Official title:

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02462811
• Other study ID #: CLCL-003
• Status: Completed
• Phase: Phase 3
• First received: May 22, 2015
• Last updated: November 2, 2016
• Start date: September 2014
• Est. completion date: August 2015

Study information

• Verified date: January 2016
• Source: Charleston Laboratories, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objectives of this study are to compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco®, and to demonstrate the efficacy of CL-108 when compared to placebo for the relief of moderate to severe pain In patients with moderate to severe pain following bunionectomy (osteotomy with fixation of the head of the first metatarsal bone).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 552
• Est. completion date: August 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA

• Informed Consent: Signed consent obtained at screening prior to any procedures being performed.

• Gender: Male or non-pregnant and non-lactating female. A female of child-bearing potential is eligible to participate in this study if she has a negative urine pregnancy test and is using an acceptable method of birth control (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterilization)

• Age: 18 years or older

• OINV Status: At risk of OINV on the Nausea Prone Questionnaire (NPQ)

• Foot Condition: Surgical extraction of a unilateral first metatarsal bunion confirmed by foot x-ray (assessed by surgeon prior to surgery)

• Pain Severity: Presence of moderate or severe pain (i.e., = 4 on the baseline numerical pain intensity rating scale [PI-NRS])

• Pain Confirm: Rating = 50 mm on the baseline visual analog pain intensity scale (PI-VAS)

• Diary Completion: Be willing and able to record safety and efficacy information in the In-patient and Outpatient Diaries

• Safe Transportation: Patient must have arrangements for transportation home from the research center accompanied by a responsible adult

EXLUSION CRITERIA

• Medical Condition: Presence of a serious medical condition (e.g., poorly controlled hypertension or diabetes, neurological disease including Parkinson's or other condition associated with a movement disorder, significantly impaired cardiac, renal, hepatic, respiratory, or thyroid function)

• Infection: Acute local infection at the time of surgery that could confound post-surgical evaluation.

• Drug Allergy: History of hypersensitivity or allergy to an opioid drug such as hydrocodone, promethazine, acetaminophen, ondansetron, NSAID (such as ibuprofen, including aspirin) or ketorolac or history of a dystonic/dyskinetic reaction to prior anti-emetic or anti-psychotic medication

• Contraindicated Drugs: Use (within 24 hours of the surgical procedure) of any confounding prescription or non-prescription drug (e.g., analgesic, anti-emetic, sedating antihistamine, sedative, alcohol, CNS/psychotropic agent, including sleep aides, benzodiazepines, performance/attention enhancers, marijuana, anti-depressants) or any drug contraindicated with hydrocodone, acetaminophen, or promethazine (except for pre-op medications). Antibiotic prophylaxis for endocarditis (except if known to cause nausea) and ASA 62.5 mg for cardiovascular prophylaxis are permitted during the study.

• History of drug or alcohol abuse

• Caffeine Use: Ingestion of any caffeine-containing beverage or chocolate since mid-night before the operation

• Investigation Drug Use: Use of an investigational drug within the past 30 days

• Participated in Study:Previous participation in this study

• Pregnancy, Lactation: Women who are pregnant or lactating

• Participant Relation: Employee at the research center or of Charleston Laboratories or relative of the Principal Investigator, Sub-Investigators, or research staff who is directly involved in this study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Nausea
• Pain
• Vomiting

Intervention

Drug:
• CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)

• Placebo

• Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Joseph Hazelton

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The occurrence of opioid-induced nausea and vomiting (OINV) as assessed by an OINV questionnaire comparing CL-108 to Norco® over 48 hours.		48 hours	No
Primary	The relief of moderate to severe pain, assessed by visual analog pain intensity scale, comparing CL-108 to placebo over 48 hours (SPID48).		48 hours	No
Secondary	The severity of opioid-induced nausea, comparing CL-108 to Norco® over 48 hours		48 hours	No
Secondary	The occurrence of vomiting, comparing CL-108 to Norco® over 48 hours		48 hours	No
Secondary	The use of anti-emetics, comparing CL-108 to Norco® over 48 hours.		48 hours	No
Secondary	Incidence of post-discharge nausea and vomiting (PDNV), comparing CL-108 to placebo over days 3-5		48 hours	No
Secondary	The relief of post-operative nausea and vomiting (PONV), comparing CL-108 to placebo over 48 hours		48 hours	No
Secondary	The relief of severe pain, comparing CL-108 to Norco® over 48 hours, i.e., summed pain intensity differences over 48 hours (SPID48)		48 hours	No

External Links

•   Charleston Website